Evaluation of the effects of rationally

designed anti-TrkB peptides on the

proliferation and apoptosis of multiple

myeloma cells by Kafshdouziamin, Marzieh et al.
Evaluation of the effects of rationally 
designed anti-TrkB peptides on the 
proliferation and apoptosis of multiple 
myeloma cells  
Marzieh Kafshdouziamin  
1Department of Medical Biotechnology, Para Medicine School, Qazvin University of Medical 
Sciences, Qazvin, Iran 
, Mansour Poorebrahim2Department of Medical Biotechnology, School of Advanced 
Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran 
, Hamzeh Rahimi3 
Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, 
Tehran, Iran 
, Morteza Karimipoor  
4Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, 
Tehran, Iran 
, Nematollah Gheibi 
Abstract 
Inhibition of oncogenes through use of small peptides has emerged as a new promising approach 
in cancer therapy. TrkB is a proto-oncogene that its up-regulation has frequently been reported in 
the Multiple Myeloma (MM) cells. In our previous study, we have designed two potent 
inhibitory peptides based on the TrkB structure. Here, we have evaluated the effects of these 
anti-TrkB peptides on the proliferation and apoptosis of MM cell lines. The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry were used to 
measure the cell viability and apoptosis of two MM cell lines treated with designed peptides. The 
effects of designed peptides on the expression and phosphorylation of TrkB were assessed using 
western blot assay. These designed peptides could efficiently modulate cell proliferation and 
apoptosis of MM cells through inhibiting TrkB phosphorylation. Our results indicate that the 
inhibitory anti-TrkB small peptides are very potent to inhibit MM cell proliferation through 
blocking TrkB signalling pathway. 
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